Oral anticoagulants and gastrointestinal bleeding: pharmacovigilance insights from the FDA adverse event reporting system database

DOACs showed a significantly lower risk of GIB than VKAs, though dabigatran exhibited a higher risk of lower GIB compared to other OACs. Different OACs exhibited distinct risk profiles across GIB locations, providing critical insights for optimizing anticoagulation management strategies.